Pancreatic exocrine and gallbladder function during long-term treatment with octreotide (SMS 201-995).
Since octreotide (SMS 201-995, Sandostatin; Sandoz Pharmaceuticals) is a potent inhibitor of pancreatic exocrine secretion and gallbladder contraction, long-term treatment with this drug may theoretically result in impaired pancreatic function and gallstones. However, we observed excellent pancreatic exocrine function--as assessed by the PABA/PAS test--in acromegalics who received octreotide treatment for more than 6 months. Plasma cholecystokinin showed a significant, although blunted, postprandial response, which exceeded the threshold for gallbladder contraction in healthy controls. Remarkably, postprandial gallbladder contraction was completely abolished for at least 2 h during octreotide treatment. In contrast to other studies, none of 16 acromegalic patients on long-term octreotide treatment developed gallstones. Although the incidence of gallstones in patients on long-term octreotide treatment may be increased, the risk seems to be variable.
Division of Gastroenterology, University Hospital Nijmegen, The Netherlands.
W P
WP
Hopman
P A
PA
van Liessum
G F
GF
Pieters
A G
AG
Smals
A
A
Tangerman
J B
JB
Jansen
G
G
Rosenbusch
C B
CB
Lamers
P W
PW
Kloppenborg
D010129:4-Aminobenzoic Acid / Q000652:urine; D000172:Acromegaly / Q000188:drug therapy*; D010131:Aminosalicylic Acid / Q000652:urine; D002766:Cholecystokinin / Q000097:blood; D005704:Gallbladder / Q000187:drug effects*; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use*; D010179:Pancreas / Q000187:drug effects*
D010131:Aminosalicylic Acid; D002766:Cholecystokinin; D015282:Octreotide; D010129:4-Aminobenzoic Acid